Novel 1-(1-Arylimiazolin-2-Yl)-3-Arylalkilurea Derivatives with Modulatory Activity on Opioid MOP Receptors
Molecules · 2024
DOI: 10.3390/molecules29030571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Dominik Straszak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University, Chodzki 4A, 20-093 Lublin, Pol…. Hauptthemen laut MEDLINE: Receptors, Opioid, Receptors, Opioid, mu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, Medical University of Lublin, Poland.
Abstract (Originalsprache)
μ-opioid receptor ligands such as morphine and fentanyl are the most known and potent painkillers. However, the severe side effects seen with their use significantly limit their widespread use. The continuous broadening of knowledge about the properties of the interactions of the MOP receptor (human mu opioid receptor, OP3) with ligands and specific intracellular signaling pathways allows for the designation of new directions of research with respect to compounds with analgesic effects in a mechanism different from classical ligands. Allosteric modulation is an extremely promising line of research. Compounds with modulator properties may provide a safer alternative to the currently used opioids. The aim of our research was to obtain a series of urea derivatives of 1-aryl-2-aminoimidazoline and to determine their activity, mechanism of biological action and selectivity toward the MOP receptor. The obtained compounds were subjected to functional tests (cAMP accumulation and β-arrestin recruitment) in vitro. One of the obtained compounds, when administered alone, did not show any biological activity, while when co-administered with DAMGO, it inhibited β-arrestin recruitment. These results indicate that this compound is a negative allosteric modulator (NAM) of the human MOP receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University, Chodzki 4A, 20-093 Lublin, Poland.
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
- Department of Dermatology, Venereology, and Paediatric Dermatology, Faculty of Medicine, Medical University, Staszica 11, 20-080 Lublin, Poland.
- Department of Medical Informatics and Statistics, Medical University, Jaczewskiego 4, 20-090 Lublin, Poland.
ORCID-Profile: Sylwia Woźniak, Aldona Pietrzak, Dariusz Matosiuk
Förderung
- Medical University of Lublin
- Medical University of Lublin, Poland
Zitieren
APA
Straszak, D., Woźniak, S., Siwek, A., Głuch-Lutwin, M., Kołaczkowski, M., Pietrzak, A., Drop, B., & Matosiuk, D. (2024). Novel 1-(1-Arylimiazolin-2-Yl)-3-Arylalkilurea Derivatives with Modulatory Activity on Opioid MOP Receptors. Molecules. https://doi.org/10.3390/molecules29030571
Vancouver
Straszak D, Woźniak S, Siwek A, Głuch-Lutwin M, Kołaczkowski M, Pietrzak A, et al. Novel 1-(1-Arylimiazolin-2-Yl)-3-Arylalkilurea Derivatives with Modulatory Activity on Opioid MOP Receptors. Molecules. 2024. doi:10.3390/molecules29030571
BibTeX
@article{Straszak2024,
author = {Straszak, Dominik and Woźniak, Sylwia and Siwek, Agata and Głuch-Lutwin, Monika and Kołaczkowski, Marcin and Pietrzak, Aldona and Drop, Bartłomiej and Matosiuk, Dariusz},
title = {Novel 1-(1-Arylimiazolin-2-Yl)-3-Arylalkilurea Derivatives with Modulatory Activity on Opioid MOP Receptors},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29030571}
}
EUVIMED